Drug Profile


Alternative Names: ARENEGYR; CNGRC peptide-TNF alpha conjugate; NGR-hTNF; NGR-TNFα; Zafiride

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scientific Institute San Raffaele
  • Developer European Organisation for Research and Treatment of Cancer; MolMed; Scientific Institute San Raffaele
  • Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Capillary permeability modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Mesothelioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Mesothelioma
  • Phase II Colorectal cancer; Hepatocellular carcinoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma
  • Phase I Solid tumours

Most Recent Events

  • 23 Jun 2017 Regulatory submission withdrawn for Mesothelioma (Combination therapy, Late-stage disease, Second-line therapy or greater) in European Union (IV)
  • 01 Jun 2017 MolMed intends to withdraw its application for a marketing authorisation for NGR-TNF in the treatment of Mesothelioma
  • 23 Dec 2016 The EMA validates the submission of Conditional Marketing Authorisation application for NGR-TNF for Mesothelioma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top